Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aclaris Therapeutics, Inc.ACRS · Entity 5041 | Chief Business Officer | February 02, 2026 | February 06, 2026 |
| Anika Therapeutics, Inc.ANIK · Entity 6005 | EVP Business Development | July 08, 2021 | July 12, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aclaris Therapeutics, Inc.
Report date February 02, 2026 · Filed February 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 97,700 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 97,700 · Balance 97,700 F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2036-02-01 | Direct | 341,900 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 341,900 · Balance 341,900 F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2: The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F3: Exercisable with respect to 25% of the shares subject to the option vesting in four equal installments on the first, second, third and fourth anniversaries of February 2, 2026, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
Anika Therapeutics, Inc.
Report date July 08, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,592 |
Ending reported balance
After 2021-07-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-07-08 · Exercise / conversion · Acquired 3,000 · Balance 6,323 F1: Reflects the second vesting installment of RSUs granted on July 8, 2019. Row 2 · 2021-07-08 · Tax withholding · Disposed 731 · Balance 5,592 F2: Reflects an aggregate of 731 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2021. F3: Reflects the closing price of ANIK common stock on July 8, 2021, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,000 |
Reported balance
After 2021-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-07-08 · Exercise / conversion · Acquired 3,000 · Balance 3,000 F1: Reflects the second vesting installment of RSUs granted on July 8, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the second vesting installment of RSUs granted on July 8, 2019.
F2: Reflects an aggregate of 731 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2021.
F3: Reflects the closing price of ANIK common stock on July 8, 2021, the trading day on which the vesting of RSUs gave rise to tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 01, 2023 Filed Feb 3, 2023 17:01 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | Exercise / conversionCommon Stock | 11,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-006999 · doc4.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 16:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-005935 · doc4.xml · derivative · entry 2 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F3 · derivative.exercise_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. F3 · derivative.expiration_date: The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 1, 2022 16:50 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | GrantEmployee Stock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-22-005935 · doc4.xml · derivative · entry 1 Loerop James · CIK 0001781549 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2032-01-31 F1 · derivative.exercise_date: Exercisable with respect to 25% of the shares subject to the option vesting in four equal annual installments beginning on February 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 3,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004833 · ownership.xml · derivative · entry 3 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Reflects the second vesting installment of RSUs granted on July 8, 2019. F1 · derivative.expiration_date: Reflects the second vesting installment of RSUs granted on July 8, 2019. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Tax withholdingCommon Stock | 731 | $43.24 | $31,608.44 |
DisclosureSEC source: 0001171843-21-004833 · ownership.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,592 F2 · shares: Reflects an aggregate of 731 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2021. F3 · price: Reflects the closing price of ANIK common stock on July 8, 2021, the trading day on which the vesting of RSUs gave rise to tax withholding obligations. Read SEC document |
| July 08, 2021 Filed Jul 12, 2021 20:15 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-004833 · ownership.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects the second vesting installment of RSUs granted on July 8, 2019. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:14 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 16,802 | $0.00 Strike: $37.40 | $0.00 |
DisclosureSEC source: 0001171843-21-001712 · ownership.xml · derivative · entry 2 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,802 Underlying: Common Stock · 16,802 shares Expires 2031-03-09 F2 · derivative.exercise_price: Represents a 10% premium above the closing price of Anika's common stock on the date of grant. F3 · derivative.exercise_date: The premium priced stock options vest in three equal annual installments beginning on March 9, 2022. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 22:14 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 6,705 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-001712 · ownership.xml · derivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,705 Underlying: Common Stock · 6,705 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 9, 2022. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:19 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionRestricted Stock Unit · Derivative | 1,567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-001429 · ownership.xml · derivative · entry 2 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,133 Underlying: Common Stock · 1,567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each DSU represents the contingent right to receive one share of the Company's common stock. The DSUs vest in three equal annual installments beginning on February 25, 2021. F3 · derivative.expiration_date: Each DSU represents the contingent right to receive one share of the Company's common stock. The DSUs vest in three equal annual installments beginning on February 25, 2021. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 22:19 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | Exercise / conversionCommon Stock | 1,567 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-001429 · ownership.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects the first vesting installment of deferred stock units ("DSUs") granted on February 25, 2020. F2 · shares: The settlement of these DSUs shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | SaleCommon Stock | 1,244 | $35.15 | $43,726.60 |
DisclosureSEC source: 0001171843-20-004894 · ownership.xml · nonDerivative · entry 2 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,756 F2 · shares: Reflects an aggregate of 1,244 shares of common stock sold by Mr. Loerop to satisfy tax withholding obligations with respect to RSUs that vested on July 8, 2020. F3 · price: On July 9, 2020, Mr. Loerop sold 1,244 shares in one trade for $35.15. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:06 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-004894 · ownership.xml · nonDerivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · security: Reflects the first vesting installment of RSUs granted on July 8, 2019. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 23:53 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 4,700 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-001362 · ownership.xml · derivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,700 Underlying: Common Stock · 4,700 shares Expires not disclosed F1 · derivative.exercise_date: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event. F1 · derivative.expiration_date: These deferred stock units vest in full on February 25, 2021. Once vested, the settlement of these deferred stock units shall be deferred until the grantee incurs a "separation of service" as that term is defined in Section 409A of the internal revenue code, at which time the deferred stock units shall be settled in a single-lump sum within 60 days of the anniversary of such event. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $40.67 | $0.00 |
DisclosureSEC source: 0001171843-19-004474 · ownership.xml · derivative · entry 2 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-07-08 F2 · derivative.exercise_date: The stock options vest in three equal annual installments beginning July 8, 2020. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:10 UTC | Anika Therapeutics, Inc. ANIK · Entity 6005 | GrantRestricted Stock Unit · Derivative | 9,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001171843-19-004474 · ownership.xml · derivative · entry 1 Loerop James · CIK 0001781549 · EVP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires not disclosed F1 · derivative.exercise_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning July 8, 2020. F1 · derivative.expiration_date: Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning July 8, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.